Brookline Capital Acquisition Corp.

Completed

Follow

Detailed Information

Information on this SPAC.

Sponsors: Brookline Capital Holdings
IPO Size: $50M
Underwriters: Ladenburg Thalmann
Focus: Life Sciences
SEC Filings: 1814140
Public Embarc Page: https://embarc.com/capital/spac/1814140/BCAC/brookline-capital-acquisition
IPO Ticker: BCAC

SPAC Leadership

Information on the SPAC leadership.

Chief Executive Officer and ChairmanSamuel P. Wertheimer
President and DirectorScott A. Katzmann
Chief Financial OfficerPatrick A. Sturgeon
DirectorJames N. Hauslein
DirectorElgar Peerschke
DirectorTito A. Serafini, PhD
Prior Blank Check Experience

Target Information

Information on the SPAC target for merger.

Company: Apexigen
Presentation: Investor Presentation (SEC) on 2022-03-18
New Ticker: XYN BCACU BCACW
Description: Apexigen, Inc. is "a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology."